The purpose of this randomized trial is to investigate the efficacy and toxicity of percutaneous high-dose radiotherapy in patients with oligometastases of hormone refractory prostate cancer. The effectiveness will be tested in comparison to an observation group, in which no further therapy is initially given. Treatment can be stereotactically hypofractionated or conventionally fractionated.
No linked publications found in PubMed
Indication: Oligometastases (1-5) in castration-resistant prostate carcinoma Inclusion Criteria: * Patient with good general condition (WHO 0-1) * Histologically confirmed prostate carcinoma * After definitive local therapy, e.g. radical prostatectomy or definitive radiotherapy (also after neo-adjuvant hormone therapy, after postoperative radiotherapy). * PSA progression under ongoing androgen deprivation (defined as three consecutive increasing PSA values at intervals of \> 4 weeks and testosterone in the castration area \<50ng/dl or \<1.73nmol/) * Minimum duration of androgen deprivation 6 months before inclusion in study * Present complete staging (max. 6 weeks old), preferably by means of PET hybrid imaging with prostate-specific PET tracer * Imaging detection of individual active or progressive metastases (max. 5, depending on location) that are accessible to local ablative radiotherapy (histological confirmation of the metastases is not required) * No parallel participation to further clinical therapy trials up to 4 weeks before and after radiation therapy * Individual case discussion in an interdisciplinary tumor board * Patient's ability to consent and written consent Exclusion Criteria: * Severe concomitant disease that limits further life expectancy to \< 5 years according to the physician's assessment. * PSA \> 20ng/ml, testosterone \>50 dl or \>1,73nmol/l * visceral metastasis (e.g. lung, liver, brain) * lack of compliance * previous taxane-containing chemotherapy